Significance of CA19-9 in Predicting the Prognosis of Urothelial Carcinoma: A Hospital Based Study from Nepal

Asian Pacific Journal of Cancer Prevention

Volumn 14, Issue 7, 2013, Pages 4067-4069

  Jha, Dipendra Kumar ^a   Mittal, Ankush ^a   Gupta, Satrudhan Pd ^a   Sathian, Brijesh ^b  

^a Nepalese Army Institute of Health Sciences   (Nepal)

^b MANIPAL COLLEGE OF MEDICAL SCIENCES   (Nepal)

Author keywords

CA 19 9; Nepal; Prognosis; Urothelial carcinoma

Indexed keywords

CA 19-9 ANTIGEN; TUMOR MARKER;

ARTICLE; BLADDER TUMOR; BLOOD; CANCER GRADING; CANCER STAGING; CASE CONTROL STUDY; COMPARATIVE STUDY; FOLLOW UP; HOSPITAL; HUMAN; METASTASIS; NEPAL; PROGNOSIS; TUMOR INVASION;

CA-19-9 ANTIGEN; CASE-CONTROL STUDIES; FOLLOW-UP STUDIES; HOSPITALS; HUMANS; NEOPLASM GRADING; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASM STAGING; NEPAL; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 84885450425     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2013.14.7.4067     Document Type: Article

References (12)

1. Badar F, Sattar A, Meerza F, et al(2009). Carcinoma of the urinary bladder in a tertiary care setting in a developing country. Asian Pac J Cancer Prev, 10, 449-52.
2. Bastos Oreiro M, Lopez Rodriguez M, Monedero Martin MC, et al (2008). Elevation of CA 19.9 in urothelial bladder cancer. Med Clin (Barc), 130, 319.
3. Epstein JI, Amin MB, Reuter VR, et al (1998). The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder consensus conference committee. Am J Surg Pathol, 22, 1435-48.
4. Hegele A, Mecklenburg V, Varga Z, et al (2010). CA19.9 and CEA in transitional cell carcinoma of the bladder: serological and immunohistochemical findings. Anticancer Res, 30, 5195-200.
5. Herberman RB (1977). Immunologic tests in diagnosis of cancer. Am J Clin Pathol, 68, 688-98.
6. Kikuchi H (2004). Tumor markers of urinary tract carcinoma. Rinsho Byori, 52, 371-80.
7. Kong CH, Singam P, Hong GE, et al (2010). Clinicopathological features of bladder tumours in a single institution in Malaysia. Asian Pac J Cancer Prev, 11, 149-52.
8. Pall M, Iqbal J, Singh SK, et al (2012). CA 19-9 as a serum marker in urothelial carcinoma. Urol Ann, 4, 98-101.
9. Salehi A, Khezri AA, Malekmakan L, et al (2011). Epidemiologic status of bladder cancer in Shiraz, southern Iran. Asian Pac J Cancer Prev, 12, 1323-7.
10. Supit W, Mochtar CA, Sugiono M (2011). Survival of patients with transitional cell carcinoma of the urinary bladder in indonesia: a single institution review. Asian Pac J Cancer Prev, 12, 549-53.
11. Terris MK, Villers A, Freiha FS (1990). Transrectal ultrasound appearance of transitional cell carcinoma involving the prostate. J Urol, 143, 952-6.
12. Washino S, Hirai M, Matsuzaki A, et al (2011). Clinical usefulness of CEA, CA19-9, and CYFRA 21-1 as tumor markers for urothelial bladder carcinoma. Urol Int, 87, 420-8.